论文部分内容阅读
目的:研究阿苯达唑治疗广州管圆线虫病出现肝损害的临床特点。方法:收集我院2006年8～9月39例感染广州管圆线虫用阿苯达唑治疗出现肝损害患者的临床资料,并对其年龄、性别、用药情况、临床表现及预后进行统计分析。结果:39例肝损害患者中男27例(69.23%),女12例(30.77%)。平均(36.44±9.77)岁。患者口服阿苯达唑400mg,3次/d,疗程3～17d,39例患者的ALT和AST分别由(17.11±7.94)U/L升至(104.07±58.20)U/L,(14.80±3.93)U/L升至(45.48±29.77)U/L。患者经保肝治疗10个月后,其ALT和AST水平均恢复正常。结论:广州管圆线虫病患者用阿苯达唑治疗出现肝损害(ALT和AST升高)可能和剂量、疗程以及联合用药有关。患者经保肝治疗后ALT和AST水平可恢复正常。
Objective: To study the clinical features of albendazole in treatment of angiostrongychiasis of liver. Methods: The clinical data of 39 patients infected with albendazole in patients with liver damage from August to September 2006 in our hospital were collected, and their age, sex, drug use, clinical manifestations and prognosis were analyzed. Results: There were 27 males (69.23%) and 12 females (30.77%) in 39 cases of liver damage. Average (36.44 ± 9.77) years old. The ALT and AST of 39 patients increased from (17.11 ± 7.94) U / L to (104.07 ± 58.20) U / L, (14.80 ± 3.93 ) U / L increased to (45.48 ± 29.77) U / L. After 10 months of liver protection, the ALT and AST levels returned to normal. Conclusion: The treatment of angiomyolipid patients with albendazole liver damage (ALT and AST increased) may be related to dose, duration of treatment and the combination of drugs. Patients with liver protection after ALT and AST levels returned to normal.